SAB BIOTHERAPEUTICS, INC. Revenue
SAB BIOTHERAPEUTICS, INC. (SABS) reported Revenue of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-03-09
- SAB BIOTHERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-12-31 was $114.70K, a 62.40% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-06-30 was $263.14K, a 207.70% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-03-31 was $944.58K, a 62.55% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $1.32M, a 40.94% decline from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $2.24M, a 90.63% decline from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $23.90M, a 60.73% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-09 | |||
| 2024-12-31 | $114.70K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $114.70K derived: sum of 2 quarters · filed 2026-03-09 | $377.83K derived: sum of 3 quarters · filed 2026-03-09 | $1.32M 10-K · filed 2026-03-09 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $263.14K derived: sum of 2 quarters · filed 2025-11-14 | $1.21M 10-Q · filed 2025-11-14 | $1.51M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $263.14K 10-Q · filed 2025-08-07 | $1.21M 10-Q · filed 2025-08-07 | $1.51M derived: sum of 3 quarters · filed 2025-08-07 | $2.78M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $944.58K 10-Q · filed 2025-05-09 | $1.25M derived: sum of 2 quarters · filed 2025-05-09 | $2.52M derived: sum of 3 quarters · filed 2025-05-09 | $2.60M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $305.01K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.57M derived: sum of 2 quarters · filed 2025-03-31 | $1.66M derived: sum of 3 quarters · filed 2025-03-31 | $2.24M 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.27M 10-Q · filed 2024-11-06 | $1.35M derived: sum of 2 quarters · filed 2024-11-06 | $1.93M 10-Q · filed 2024-11-06 | $4.09M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $85.52K 10-Q · filed 2024-08-08 | $666.62K 10-Q · filed 2024-08-08 | $2.83M derived: sum of 3 quarters · filed 2024-08-08 | $6.42M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $581.10K 10-Q · filed 2024-05-20 | $2.74M derived: sum of 2 quarters · filed 2024-05-20 | $6.33M derived: sum of 3 quarters · filed 2024-05-20 | $12.68M derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | $2.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $5.75M derived: sum of 2 quarters · filed 2024-03-29 | $12.10M derived: sum of 3 quarters · filed 2024-03-29 | $23.90M 10-K · filed 2024-03-29 |
| 2022-09-30 | $3.59M 10-Q · filed 2023-11-13 | $9.94M derived: sum of 2 quarters · filed 2023-11-13 | $21.74M 10-Q · filed 2023-11-13 | $32.80M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $6.35M 10-Q · filed 2023-08-21 | $18.15M 10-Q · filed 2023-08-21 | $29.21M derived: sum of 3 quarters · filed 2023-08-21 | $43.89M derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-03-31 | $11.80M 10-Q · filed 2023-05-15 | $22.86M derived: sum of 2 quarters · filed 2023-05-15 | $37.54M derived: sum of 3 quarters · filed 2023-05-15 | $55.75M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $11.06M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-28 | $25.74M derived: sum of 2 quarters · filed 2023-04-28 | $43.95M derived: sum of 3 quarters · filed 2023-04-28 | $60.88M 10-K/A · filed 2023-04-28 |
| 2021-09-30 | $14.68M 10-Q · filed 2022-11-14 | $32.89M derived: sum of 2 quarters · filed 2022-11-14 | $49.82M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $18.21M 10-Q · filed 2022-08-10 | $35.14M 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | $16.93M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $55.24M 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |